Athanasios Karampeazis

492 citations

26 papers · 317 indexed · h-index 10

Impact in

Oncology top 10%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Bone health and treatments
- Cancer Treatment and Pharmacology
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in ⓘ

Oncology 21
- Colorectal Cancer Treatments and Studies 10
- Cancer Treatment and Pharmacology 5
- Lung Cancer Research Studies 5
- Cancer Diagnosis and Treatment 3
Pulmonary and Respiratory Medicine 15
- Lung Cancer Treatments and Mutations 13
- Lung Cancer Diagnosis and Treatment 8

Co-authors: Lambros Vamvakas (7 shared papers)Vassilis Georgoulias (8 shared papers)John Souglakos (6 shared papers)Sofia Agelaki (6 shared papers)L. Vamvakas (9 shared papers)Αthanasios Kotsakis (8 shared papers)Athanasios Pallis (6 shared papers)V. Georgoulias (3 shared papers)
Journals: Journal of Clinical Oncology (5 papers)Journal of Geriatric Oncology (4 papers)Clinical Lung Cancer (3 papers)Oncology (3 papers)Critical Reviews in Oncology/Hematology (2 papers)
Partner nations: Greece United Kingdom United States

In The Last Decade

Athanasios Karampeazis

22 papers receiving 310 citations

Peers

Countries citing papers authored by Athanasios Karampeazis

Since Specialization

Citations

This map shows the geographic impact of Athanasios Karampeazis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Athanasios Karampeazis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Athanasios Karampeazis more than expected).

Fields of papers citing papers by Athanasios Karampeazis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Athanasios Karampeazis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Athanasios Karampeazis. The network helps show where Athanasios Karampeazis may publish in the future.

Co-authors

The 25 scholars most cited alongside Athanasios Karampeazis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Athanasios Karampeazis Line = papers co-authored together Athanasios Karampeazis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study Cancer ·Athanasios Karampeazis, Alexandra Voutsina, John Souglakos, Nikos Kentepozidis, Stelios Giassas, Charalambos Christofillakis, Αthanasios Kotsakis, Pavlos Papakotoulas, Ageliki Rapti, M. Agelidou, Sofia Agelaki, Lambros Vamvakas, George Samonis, Dimitris Mavroudis, Vassilis Georgoulias	2013	90
2	Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. Journal of Clinical Oncology ·L. Vamvakas, Sofia Agelaki, Ν. Kentepozidis, Athanasios Karampeazis, Athanasios Pallis, C. Christophyllakis, Α. Kotsakis, Ioannis Boukovinas, D. Mavroudis, V. Georgoulias	2010	35
3	Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG) Critical Reviews in Oncology/Hematology ·L. Vamvakas, A. Athanasiadis, Athanasios Karampeazis, S. Kakolyris, A. Polyzos, Ch. Kouroussis, N. Ziras, Kostas Kalbakis, Vassilis Georgoulias, John Souglakos	2009	28
4	Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review Oral Surgery Oral Medicine Oral Pathology and Oral Radiology ·Ourania Nicolatou‐Galitis, Evangelia Razis, Dimitra Galiti, Evangelos Galitis, Stefanos Labropoulos, Antonios Tsimpidakis, Joseph Sgouros, Athanasios Karampeazis, César A. Migliorati	2015	25
5	The Relevance and Added Value of Geriatric Medicine (GM): Introducing GM to Non-Geriatricians Journal of Clinical Medicine ·Marina Kotsani, Evrydiki Kravvariti, Christina Avgerinou, Symeon Panagiotakis, Aikaterini Bograkou - Tzanetakou, Eleftheria Antoniadou, Georgios Karamanof, Athanasios Karampeazis, Anastasia Koutsouri, Kyriaki Panagiotopoulou, George Soulis, Konstantinos Stolakis, Ioannis Georgiopoulos, Athanase Bénétos	2021	20
6	Docetaxel Vs. Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: A Hellenic Oncology Research Group Randomized Phase III Study Clinical Lung Cancer ·Athanasios Karampeazis, Lambros Vamvakas, Athina Agelidou, Nikolaos Kentepozidis, Kyriakos Chainis, Vassilis Chandrinos, N. Vardakis, Athanasios Pallis, Charalambos Christophyllakis, Vassilis Georgoulias	2011	17
7	Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG) BMC Cancer ·Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, Dora Hatzidaki, S. Kakolyris, Charalampos Christophylakis, Ioannis Boukovinas, Aris Polyzos, Vassilis Georgoulias, John Souglakos	2014	14
8	Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group Annals of Oncology ·Athanasios Pallis, Athanasios Karampeazis, L. Vamvakas, N. Vardakis, Αthanasios Kotsakis, V. Bozionelou, A. Kalykaki, Dora Hatzidaki, Dimitriοs Mavroudis, V. Georgoulias	2011	12
9	Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study Journal of Geriatric Oncology ·Athanasios Karampeazis, Lambros Vamvakas, Αthanasios Kotsakis, Charalambos Christophyllakis, Nikolaos Kentepozidis, V. Chandrinos, Anna Agelidou, Aris Polyzos, Xanthi Tsiafaki, Dora Hatzidaki, Vassilis Georgoulias	2016	11
10	Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non–Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group Clinical Lung Cancer ·Athanasios Karampeazis, Lambros Vamvakas, Nikolaos Kentepozidis, Aris Polyzos, Vassilis Chandrinos, George Rigas, Charalambos Christofyllakis, Αthanasios Kotsakis, Dora Hatzidaki, Athanasios Pallis, Vassilis Georgoulias	2016	10
11	Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial. Journal of Clinical Oncology ·Athanasios Karampeazis, L. Vamvakas, Athanasios Pallis, C. Christophyllakis, Ν. Kentepozidis, V. Chandrinos, Aris Polyzos, A. Athanasiadis, Georgia Milaki, V. Georgoulias	2010	9
12	Advanced Non–Small-Cell Lung Cancer in the Elderly Clinical Lung Cancer ·Lambros Vamvakas, Emmanouil Saloustros, Athanasios Karampeazis, Vassilis Georgoulias	2009	8
13	A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors Oncology ·A. Kalykaki, L. Vamvakas, Sofia Agelaki, Kostas Kalbakis, N. Vardakis, G. Sfakiotaki, M. Ignatiadis, Zacharenia Saridaki, Athanasios Karampeazis, D. Mavroudis, V. Georgoulias	2006	7
14	Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG) Journal of Geriatric Oncology ·Natalia Asimakopoulou, John Souglakos, Nikolaos Kentepozidis, Athanasios Karampeazis, Αthanasios Kotsakis, Nikolaos Ziras, Paris Makrantonakis, Efthimios Prinarakis, Lambros Vamvakas, Vassilis Georgoulias	2018	7
15	Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial Journal of Clinical Oncology ·Athanasios Karampeazis, L. Vamvakas, Athina Agelidou, V. Chandrinos, Xanthi Tsiafaki, C. Christophylakis, Kyriakos Chainis, S. Kakolyris, A. Kalykaki, D. Mavroudis	2007	6
16	Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy. Journal of Clinical Oncology ·Athanasios Karampeazis, L. Vamvakas, Sofia Agelaki, Alexandros Xyrafas, Athanasios Pallis, Emmanouil Saloustros, Zoe Giannousi, Kostas Kalbakis, D. Mavroudis, V. Georgoulias	2011	5
17	Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) Cancer Chemotherapy and Pharmacology ·Ioannis Boukovinas, Nikolaos Androulakis, Nikolaos Kentepozidis, Aris Polyzos, Pavlos Papakotoulas, Nikolaos Ziras, Αthanasios Kotsakis, N. Vardakis, Athanasios Karampeazis, Vassilis Markos, A. Kostakopoulos, C. Constantinides, George Samonis, Dimitris Mavroudis, Vassilis Georgoulias	2011	4
18	Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group Oncology ·Sofia Agelaki, Dora Hatzidaki, Αthanasios Kotsakis, Pavlos Papakotoulas, Aris Polyzos, Nikolaos Ziras, Ioannis Gioulbasanis, Athanasios Karampeazis, Athina Agelidou, Xanthi Tsiafaki, Vassilis Chandrinos, Μαρία Λερίκου, Vassilis Georgoulias	2010	3
19	A Dose Escalation Study of the Biweekly Administration of Paclitaxel, Oxaliplatin and Capecitabine in Patients with Advanced Solid Tumors Oncology ·Zacharenia Saridaki, V. Bozionelou, Nikolaos Kentepozidis, Αthanasios Kotsakis, Nikolaos Vardakis, A. Kalykaki, Ioannis Gioulbasanis, Athanasios Karampeazis, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis	2007	2
20	Propranolol and Weekly Paclitaxel in the Treatment of Metastatic Heart Angiosarcoma Cureus ·Oraianthi Fiste, Apostolos Dimos, Vasiliki- Elpida Kardara, Konstantinos Ballasis, Athanasios Karampeazis	2020	2

About Athanasios Karampeazis

Athanasios Karampeazis is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Economics and Econometrics and Cancer Research, having authored 26 papers that have together received 317 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers), Lung Cancer Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (5 papers), Lung Cancer Research Studies (5 papers), Genetic factors in colorectal cancer (3 papers), Economic and Financial Impacts of Cancer (3 papers) and Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (245 citations), Pulmonary and Respiratory Medicine (221 citations), Geriatrics and Gerontology (25 citations), Neuropsychology and Physiological Psychology (5 citations) and Hepatology (22 citations). Athanasios Karampeazis has collaborated with scholars based in Greece, United Kingdom and United States. Frequent co-authors include Lambros Vamvakas, Vassilis Georgoulias, John Souglakos, Sofia Agelaki, L. Vamvakas, Αthanasios Kotsakis, Athanasios Pallis, V. Georgoulias, M. Agelidou and Alexandra Voutsina. Their work appears in journals such as Journal of Clinical Oncology, Journal of Geriatric Oncology, Clinical Lung Cancer, Oncology and Critical Reviews in Oncology/Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact